2018 Q3 Form 10-Q Financial Statement

#000156459018028092 Filed on November 07, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2017 Q4 2017 Q3
Revenue $18.82M $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.280M $2.510M $1.810M
YoY Change 81.22% 91.6% 43.65%
% of Gross Profit
Research & Development $4.346M $3.780M $2.940M
YoY Change 47.84% 89.95% -15.52%
% of Gross Profit
Depreciation & Amortization $20.00K $10.00K $10.00K
YoY Change 100.0% -50.0% 0.0%
% of Gross Profit
Operating Expenses $7.624M $6.289M $4.756M
YoY Change 60.29% 90.26% 0.23%
Operating Profit $11.20M -$6.289M -$4.756M
YoY Change -335.44% 90.26% 0.23%
Interest Expense $333.0K $50.00K $60.00K
YoY Change 455.08% -121.74% -135.29%
% of Operating Profit 2.97%
Other Income/Expense, Net $339.4K $53.83K $106.7K
YoY Change 218.21% -125.32% -176.04%
Pretax Income $11.54M -$6.240M -$4.650M
YoY Change -348.17% 77.27% -4.91%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings $11.54M -$6.235M -$4.650M
YoY Change -348.14% 77.23% -4.83%
Net Earnings / Revenue 61.3%
Basic Earnings Per Share
Diluted Earnings Per Share $4.22 -$3.45 -$2.58
COMMON SHARES
Basic Shares Outstanding 40.53M 26.93M
Diluted Shares Outstanding 40.96M 26.93M

Balance Sheet

Concept 2018 Q3 2017 Q4 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $68.80M $20.30M $24.90M
YoY Change 176.31%
Cash & Equivalents $68.81M $20.26M $24.83M
Short-Term Investments $0.00 $100.0K
Other Short-Term Assets $1.200M $322.2K $900.0K
YoY Change 33.33% 54.14%
Inventory
Prepaid Expenses $313.1K
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $70.00M $20.90M $25.90M
YoY Change 170.27% 838.74%
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K $107.2K $100.0K
YoY Change 0.0% -28.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $0.00
YoY Change
Total Long-Term Assets $200.0K $128.2K $100.0K
YoY Change 100.0% -24.84%
TOTAL ASSETS
Total Short-Term Assets $70.00M $20.90M $25.90M
Total Long-Term Assets $200.0K $128.2K $100.0K
Total Assets $70.20M $21.03M $26.00M
YoY Change 170.0% 777.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $717.0K $1.277M $855.4K
YoY Change -16.18% 12.41%
Accrued Expenses $2.900M $2.300M $1.700M
YoY Change 70.59%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.645M $3.592M $2.600M
YoY Change 40.18% -75.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.645M $3.592M $2.600M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $3.600M $3.600M $2.600M
YoY Change 38.46%
SHAREHOLDERS EQUITY
Retained Earnings -$110.4M -$108.6M
YoY Change 25.92%
Common Stock $177.0M $126.0M
YoY Change 101611307.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $66.52M $17.44M $23.40M
YoY Change
Total Liabilities & Shareholders Equity $70.16M $21.03M $26.00M
YoY Change 169.85% 777.29%

Cashflow Statement

Concept 2018 Q3 2017 Q4 2017 Q3
OPERATING ACTIVITIES
Net Income $11.54M -$6.235M -$4.650M
YoY Change -348.14% 77.23% -4.83%
Depreciation, Depletion And Amortization $20.00K $10.00K $10.00K
YoY Change 100.0% -50.0% 0.0%
Cash From Operating Activities -$6.220M -$4.610M -$4.020M
YoY Change 54.73% 51.64% -16.77%
INVESTING ACTIVITIES
Capital Expenditures $20.00K $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $50.00K
YoY Change
Cash From Investing Activities -$20.00K $50.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.270M 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -6.220M -4.610M -4.020M
Cash From Investing Activities -20.00K 50.00K 0.000
Cash From Financing Activities 6.270M 0.000 0.000
Net Change In Cash 30.00K -4.560M -4.020M
YoY Change -100.75% -1570.97% 1240.0%
FREE CASH FLOW
Cash From Operating Activities -$6.220M -$4.610M -$4.020M
Capital Expenditures $20.00K $0.00 $0.00
Free Cash Flow -$6.240M -$4.610M -$4.020M
YoY Change 55.22% 51.64% -16.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68807267
CY2018Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
317562
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
317562
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1912980
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1612700
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
52099
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
124949
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2436229
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
912403
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.28
CY2017Q4 arpo Accrued Project Costs Current
AccruedProjectCostsCurrent
1069852
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0285
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6512
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.13
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.24
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0283
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6604
us-gaap Share Based Compensation
ShareBasedCompensation
2763890
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3644685
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
4059
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
2707
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
176953759
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
125995438
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110440702
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
66517116
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
70161801
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40588004
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40588004
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18821953
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20155286
CY2018Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
arpo:LicenseRevenueAndOtherMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
arpo:LicenseRevenueAndOtherMember
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8366869
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6732816
us-gaap Operating Expenses
OperatingExpenses
22470352
us-gaap Operating Expenses
OperatingExpenses
15099685
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12604125
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9866227
us-gaap Operating Income Loss
OperatingIncomeLoss
-2315066
us-gaap Operating Income Loss
OperatingIncomeLoss
-15099685
arpo Grant Income
GrantIncome
6394
arpo Grant Income
GrantIncome
93720
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
430626
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-159612
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-65892
us-gaap Net Income Loss
NetIncomeLoss
-15165577
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
11537478
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4649567
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40527722
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26926673
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31687434
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19889984
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40961620
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26926673
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31687434
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19889984
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
76756
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
48119027
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2763890
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3502543
us-gaap Depreciation
Depreciation
35312
us-gaap Depreciation
Depreciation
39269
us-gaap Share Based Compensation
ShareBasedCompensation
394268
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
75561
us-gaap Paid In Kind Interest
PaidInKindInterest
204929
arpo Increase Decrease In Prepaid Research And Development Contracts
IncreaseDecreaseInPrepaidResearchAndDevelopmentContracts
24052
arpo Increase Decrease In Prepaid Research And Development Contracts
IncreaseDecreaseInPrepaidResearchAndDevelopmentContracts
-238658
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
572870
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
656896
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
52521
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
598706
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
376755
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14271082
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29380
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6547
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29380
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6547
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
76756
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
36101
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
297354
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
51621570
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
40247775
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3084385
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48195783
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37496845
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
48543158
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
23219216
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1609694
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24828910
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
74701187
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
13447934
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reclassification</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain prior year balances within the condensed consolidated statement of cash flows were reclassified to conform with current period presentation.&#160;As a result of the current year reclassification, there were no changes in any subtotals of the condensed consolidated statement of cash flows.</p></div>
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q1 arpo Capital Stock Conversion Basis Ratio
CapitalStockConversionBasisRatio
2.3336572
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls and in developing the estimates and assumptions used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: grant date fair value of the Company&#8217;s stock-based awards, accrued expenses, revenue recognition and income taxes. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s results can also be affected by economic, political, legislative, regulatory, and legal actions. Economic conditions, such as recessionary trends, inflation, interest and monetary exchange rates, government fiscal policies, and changes in the prices of research studies, can have a significant effect on operations. While the Company maintains reserves for anticipated liabilities and carries various levels of insurance, the Company could be affected by civil, criminal, regulatory or administrative actions, claims or proceedings. </p></div>
CY2018Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2017Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2018Q3 arpo Number Of Financial Institutions
NumberOfFinancialInstitutions
2
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Off-Balance Sheet Risk </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents are the only financial instruments that potentially subject the Company to concentrations of credit risk. At September&#160;30, 2018, and December&#160;31, 2017, all the Company&#8217;s cash was deposited in accounts at two principal financial institutions. The Company maintains its cash and cash equivalents with high-quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk. The Company has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements. </p></div>
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3348632
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.72
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.64
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.47
CY2017Q4 arpo Number Of Financial Institutions
NumberOfFinancialInstitutions
2
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
717000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1276537
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.23
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.73
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.27
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.28
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
499835
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
277217
CY2018Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1077901
CY2017Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
833650
CY2018Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
228048
CY2017Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
69549
CY2018Q3 arpo Accrued Project Costs Current
AccruedProjectCostsCurrent
1032787
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
89114
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
65359
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2018Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.00
CY2017Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.00
arpo Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P3Y
CY2017 arpo Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P3Y
arpo Class Of Warrant Or Right Expiration Date
ClassOfWarrantOrRightExpirationDate
2020-03-15
CY2017 arpo Class Of Warrant Or Right Expiration Date
ClassOfWarrantOrRightExpirationDate
2020-03-15
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M26D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M19D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y4M28D
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P5Y11M15D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2738704
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1129828
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
61555
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1068273
CY2018Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4568480
CY2018Q3 us-gaap Share Based Compensation
ShareBasedCompensation
806411
CY2017Q3 us-gaap Share Based Compensation
ShareBasedCompensation
127359
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
arpo Tax Cuts And Jobs Act Of2017 Incomplete Accounting Adjustments Of Provisional Income Tax Expense Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingAdjustmentsOfProvisionalIncomeTaxExpenseBenefit
0
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
116640
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
155513
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
31653
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
125660
CY2018Q3 arpo Operating Leases Future Minimum Payments Due In Three Years And Thereafter
OperatingLeasesFutureMinimumPaymentsDueInThreeYearsAndThereafter
187466
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
344779
CY2018Q2 us-gaap Proceeds From License Fees Received
ProceedsFromLicenseFeesReceived
20000000
arpo Revenue Performance Obligation Expected Timing Of Satisfaction Period
RevenuePerformanceObligationExpectedTimingOfSatisfactionPeriod
P90D

Files In Submission

Name View Source Status
0001564590-18-028092-index-headers.html Edgar Link pending
0001564590-18-028092-index.html Edgar Link pending
0001564590-18-028092.txt Edgar Link pending
0001564590-18-028092-xbrl.zip Edgar Link pending
arpo-10q_20180930.htm Edgar Link pending
arpo-20180930.xml Edgar Link completed
arpo-20180930.xsd Edgar Link pending
arpo-20180930_cal.xml Edgar Link unprocessable
arpo-20180930_def.xml Edgar Link unprocessable
arpo-20180930_lab.xml Edgar Link unprocessable
arpo-20180930_pre.xml Edgar Link unprocessable
arpo-ex311_6.htm Edgar Link pending
arpo-ex312_9.htm Edgar Link pending
arpo-ex321_8.htm Edgar Link pending
arpo-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending